Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
Pneumococcus is an important cause of community acquired pneumonia and the commonest cause of community acquired bacterial pneumonia. It also causes invasive pneumococcal disease that increases hospitalization rates, economic burden, morbidity and mortality. Apart from children below 5 years, adult...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Makhdoomi Printers
2024-02-01
|
| Series: | Global Journal of Medicine and Public Health |
| Subjects: | |
| Online Access: | http://www.nicpd.ac.in/ojs-/index.php/gjmedph/article/view/3698 |
| _version_ | 1797321533556785152 |
|---|---|
| author | Salil Bendre Vikrant Tari Varsha Narayanan |
| author_facet | Salil Bendre Vikrant Tari Varsha Narayanan |
| author_sort | Salil Bendre |
| collection | DOAJ |
| description |
Pneumococcus is an important cause of community acquired pneumonia and the commonest cause of community acquired bacterial pneumonia. It also causes invasive pneumococcal disease that increases hospitalization rates, economic burden, morbidity and mortality. Apart from children below 5 years, adults 65 years or more, and all adults with underlying medical conditions or immunodeficiency are at increased risk of pneumococcal infection. For these adult groups pneumococcal vaccination that includes the 23-valent polysaccharide vaccine (PPSV23) is recommended that has shown to reduce risk of severe pneumococcal pneumonia, invasive pneumococcal disease, hospitalization rates, and mortality. However, awareness and practical implementation of adult pneumococcal vaccination is concerningly low. Surveys, awareness programs, and counseling, at the community level, as well as with physicians in primary care, have shown significant improvements in adult pneumococcal vaccination rates.
|
| first_indexed | 2024-03-08T04:59:57Z |
| format | Article |
| id | doaj.art-fb183df04e9b47b7b7121de88f121d0e |
| institution | Directory Open Access Journal |
| issn | 2277-9604 |
| language | English |
| last_indexed | 2024-03-08T04:59:57Z |
| publishDate | 2024-02-01 |
| publisher | Makhdoomi Printers |
| record_format | Article |
| series | Global Journal of Medicine and Public Health |
| spelling | doaj.art-fb183df04e9b47b7b7121de88f121d0e2024-02-07T13:59:47ZengMakhdoomi PrintersGlobal Journal of Medicine and Public Health2277-96042024-02-01123Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical AspectsSalil Bendre0Vikrant Tari1Varsha Narayanan2Professor and HeadConsultant DiabetologistMedical Affairs Consultant and Advisor, Vaximune, G C Chemie Pvt Ltd, Mumbai Pneumococcus is an important cause of community acquired pneumonia and the commonest cause of community acquired bacterial pneumonia. It also causes invasive pneumococcal disease that increases hospitalization rates, economic burden, morbidity and mortality. Apart from children below 5 years, adults 65 years or more, and all adults with underlying medical conditions or immunodeficiency are at increased risk of pneumococcal infection. For these adult groups pneumococcal vaccination that includes the 23-valent polysaccharide vaccine (PPSV23) is recommended that has shown to reduce risk of severe pneumococcal pneumonia, invasive pneumococcal disease, hospitalization rates, and mortality. However, awareness and practical implementation of adult pneumococcal vaccination is concerningly low. Surveys, awareness programs, and counseling, at the community level, as well as with physicians in primary care, have shown significant improvements in adult pneumococcal vaccination rates. http://www.nicpd.ac.in/ojs-/index.php/gjmedph/article/view/3698Pneumococcal vaccination, 23-valent polysaccharide vaccine, pneumococcal pneumonia, invasive pneumococcal disease, adult vaccination |
| spellingShingle | Salil Bendre Vikrant Tari Varsha Narayanan Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects Global Journal of Medicine and Public Health Pneumococcal vaccination, 23-valent polysaccharide vaccine, pneumococcal pneumonia, invasive pneumococcal disease, adult vaccination |
| title | Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects |
| title_full | Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects |
| title_fullStr | Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects |
| title_full_unstemmed | Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects |
| title_short | Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects |
| title_sort | vaccination in adults with 23 valent pneumococcal polysaccharide vaccine abc awareness benefits and clinical aspects |
| topic | Pneumococcal vaccination, 23-valent polysaccharide vaccine, pneumococcal pneumonia, invasive pneumococcal disease, adult vaccination |
| url | http://www.nicpd.ac.in/ojs-/index.php/gjmedph/article/view/3698 |
| work_keys_str_mv | AT salilbendre vaccinationinadultswith23valentpneumococcalpolysaccharidevaccineabcawarenessbenefitsandclinicalaspects AT vikranttari vaccinationinadultswith23valentpneumococcalpolysaccharidevaccineabcawarenessbenefitsandclinicalaspects AT varshanarayanan vaccinationinadultswith23valentpneumococcalpolysaccharidevaccineabcawarenessbenefitsandclinicalaspects |